−2.65 TWD
−337.99 M TWD
25.85 M TWD
70.06 M
About INTECH BIOPHARM LTD
Sector
CEO
Wei Hsiu Wu
Headquarters
Taipei
Website
Founded
2010
ISIN
TW0006461007
FIGI
BBG006S3TQF4
Intech Biopharm Ltd. engages in the development of drugs for obstructive airway diseases such as bronchial asthma and chronic obstructive pulmonary disease. Its products include HFA metered dosage inhaler; respiratory drugs; and oncology drugs. The company was founded on October 28, 2010 and is headquartered in Taipei, Taiwan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 6461 is 27.25 TWD — it has increased by 1.32% in the past 24 hours. Watch INTECH BIOPHARM LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange INTECH BIOPHARM LTD stocks are traded under the ticker 6461.
6461 stock has risen by 3.07% compared to the previous week, the month change is a −1.47% fall, over the last year INTECH BIOPHARM LTD has showed a −12.10% decrease.
6461 reached its all-time high on Jul 15, 2014 with the price of 122.95 TWD, and its all-time low was 11.10 TWD and was reached on Mar 23, 2020. View more price dynamics on 6461 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
6461 stock is 2.95% volatile and has beta coefficient of 0.69. Track INTECH BIOPHARM LTD stock price on the chart and check out the list of the most volatile stocks — is INTECH BIOPHARM LTD there?
Today INTECH BIOPHARM LTD has the market capitalization of 3.66 B, it has increased by 0.57% over the last week.
Yes, you can track INTECH BIOPHARM LTD financials in yearly and quarterly reports right on TradingView.
6461 net income for the last quarter is −95.99 M TWD, while the quarter before that showed −92.62 M TWD of net income which accounts for −3.64% change. Track more INTECH BIOPHARM LTD financial stats to get the full picture.
No, 6461 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 27, 2024, the company has 82.00 employees. See our rating of the largest employees — is INTECH BIOPHARM LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTECH BIOPHARM LTD EBITDA is −261.00 M TWD, and current EBITDA margin is −917.04%. See more stats in INTECH BIOPHARM LTD financial statements.
Like other stocks, 6461 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTECH BIOPHARM LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTECH BIOPHARM LTD technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTECH BIOPHARM LTD stock shows the sell signal. See more of INTECH BIOPHARM LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.